The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Aged 18-75, male and female, with ECOG score of 0 or 1;
Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
underwent PD-L1 IHC examination before therapy;
The expected survival was more than 26 weeks;
The function of liver and kidney was seriously abnormal;
Preparation for pregnant, pregnant and lactating women;
Inability to lie flat for half an hour;
Suffering from claustrophobia or other mental disorders;
patients with lung cancer, melanoma or other solid tumors scheduled for immunotherapy or combined immunotherapy; underwent PD-L1 IHC examination before therapy
Cohort
Prospective
Not listed
MPR
major pathological response, in the surgical pathology after neo-adjuvant immunotherapy, the proportion of active tumors was less than 10%.
ORR
Overall Response Rate
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
